Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Project BioShield Compromise In House Could Serve As Senate Template

This article was originally published in The Gray Sheet

Executive Summary

A funding compromise between the White House and the House Energy & Commerce Committee for Project BioShield portends a similar agreement in the Senate

You may also be interested in...



Capitol Hill In Brief

MDUFMA oversight: Senate HELP Committee Chairman Judd Gregg (R-N.H.) is committed to ensuring that FDA receives the maximum funding needed to implement the Medical Device User Fee & Modernization Act, health counsel Steve Irizarry affirms at the Banc of America Securities Washington Healthcare Policy meeting May 7. "It's something that is apparently important to the Administration, to the FDA and to my boss, and we'll do everything we can, particularly my boss, [who] is an appropriator, to make sure FDA gets the requisite amounts," Irizarry pledged...

Bioshield Legislation Headed To Senate Floor Despite Objections Of Sen. Byrd

The Senate sponsors of a bill to authorize Project Bioshield will move the legislation to the floor even if a funding compromise cannot be reached with Senate Appropriations Committee Ranking Member Robert Byrd (D-W.Va.), according Senate HELP Committee staffers

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel